Anebulo Pharmaceuticals (ANEB) Income towards Parent Company (2020 - 2025)

Anebulo Pharmaceuticals (ANEB) has reported Income towards Parent Company for 6 consecutive years, with -$2.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Income towards Parent Company rose 4.82% year-over-year to -$2.6 million; the TTM figure through Dec 2025 stood at -$10.5 million (down 22.81% YoY), while the FY2025 annual figure was -$9.4 million, down 13.39% from the prior year.
• Income towards Parent Company rose to -$2.6 million in Q4 2025 per ANEB's latest filing, from -$3.6 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$555832.0 in Q1 2021 and bottomed at -$7.2 million in Q2 2023.
• Historically, Income towards Parent Company has averaged -$3.0 million across 5 years, with a median of -$2.8 million in 2023.
• Annual changes were most pronounced in 2021 — Income towards Parent Company tumbled 955.55% — and 2024, when it surged 80.52%.
• Anebulo Pharmaceuticals' Income towards Parent Company stood at -$3.5 million in 2021, then retreated by 13.64% to -$3.9 million in 2022, then increased by 28.4% to -$2.8 million in 2023, then increased by 5.0% to -$2.7 million in 2024, then rose by 4.82% to -$2.6 million in 2025.
• Business Quant data shows ANEB's Income towards Parent Company at -$2.6 million in Q4 2025, -$3.6 million in Q3 2025, and -$2.2 million in Q2 2025.